NasdaqGM:NRIXBiotechs
Nurix Therapeutics (NRIX): Assessing Valuation After Promising NX-1607 Clinical Data Spurs Positive Sentiment
Nurix Therapeutics (NRIX) recently presented new data from its ongoing Phase 1 study of NX-1607, an oral CBL-B inhibitor, at a major immunotherapy conference. The study highlighted encouraging immune responses and pharmacologic activity in patients with advanced solid tumors.
See our latest analysis for Nurix Therapeutics.
Encouraging clinical results for NX-1607 and the appointment of industry veteran Dr. Roger Dansey to the board have sparked renewed attention for Nurix Therapeutics. While...